NEW YORK (GenomeWeb) – AltheaDx and SinfoniaRx announced on Tuesday a deal to integrate AltheaDx's IDgenetix proprietary genetic testing into Sinfonia's medication therapy management (MTM) programs directed at mental illness.
Assurance Health and Wellness Centers in Phoenix andTucson, Arizona will initially offer the enhanced MTM service, the companies said, adding that the deal will result in "an unprecedented level of drug therapy optimization and customization for individual patients."
SinfoniaRx and Assurance Health andWellnessCentersare wholly owned subsidiaries of Sinfonia Healthcare.
Financial and other terms of the deal were not disclosed.
"The testing offered by AltheaDx will allow us to better understand how our patients will respond to medications based on their own genetic profile," SinfoniaRx Founder and CEO Kevin Boesen said in a statement.
AltheaDx CEO Greg Hamilton added that his firm's research has suggested that genetic testing can identify "more than twice the number of potential drug-related problems when compared to usual practice."
AltheaDx is headquartered in San Diego and offers tests for use by clinicians to tailor treatments for cardiovascular disease, neuropsychiatric disorders, and pain. The company filed to go public in December with plans to raise up to $69 million in proceeds but withdrew those plans in March citing unattractive terms.